Eleven Biotherapeutics, a clinical-stage biotech developing protein therapeutics to treat dry eye diseases, raised $50 million by offering 5.0 million shares at $10, below the range of $13 to $15. Eleven Biotherapeutics plans to list on the NASDAQ under the symbol EBIO. Eleven Biotherapeutics initially filed confidentially on 11/7/2013. Citi, Cowen & Company and Leerink Partners acted as joint bookrunners on the deal.
